Activity and Safety of Regorafenib in Patients With Metastatic Soft Tissue Sarcoma Previously Treated With Anthracycline-based Chemotherapy : a Multinational, Randomized, Phase II, Placebo-controlled Trial
Latest Information Update: 12 Jul 2022
At a glance
- Drugs Regorafenib (Primary)
- Indications Leiomyosarcoma; Liposarcoma; Soft tissue sarcoma; Synovial sarcoma; Uterine cancer
- Focus Therapeutic Use
- Acronyms REGO-SARC; REGOSARC
- 07 Jun 2022 Results of an updated analysis of pooled cohorts ( B, C, D and E) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 08 Apr 2021 Status changed from active, no longer recruiting to completed.
- 06 Jan 2020 Results (n=37) published in the European Journal of Cancer